Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.
de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van Der Wieken R, Van De Werf F, Braunwald E. de Lemos JA, et al. Among authors: murphy sa. Circulation. 2000 Jan 25;101(3):239-43. doi: 10.1161/01.cir.101.3.239. Circulation. 2000. PMID: 10645918 Clinical Trial.
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E. Gibson CM, et al. Among authors: murphy sa. Am J Cardiol. 1999 Nov 1;84(9):976-80. doi: 10.1016/s0002-9149(99)00483-x. Am J Cardiol. 1999. PMID: 10569649 Clinical Trial.
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.
Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. Morrow DA, et al. Among authors: murphy sa. Circulation. 2000 Oct 24;102(17):2031-7. doi: 10.1161/01.cir.102.17.2031. Circulation. 2000. PMID: 11044416
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Gibson CM, Goel M, Murphy SA, Dotani I, Marble SJ, Deckelbaum LI, Dodge JT, King SB 3rd; Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Gibson CM, et al. Among authors: murphy sa. Am J Cardiol. 2000 Dec 15;86(12):1375-7, A5. doi: 10.1016/s0002-9149(00)01247-9. Am J Cardiol. 2000. PMID: 11113417 Clinical Trial.
Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group.
Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Gibson CM, et al. Among authors: murphy sa. Am J Cardiol. 2001 Feb 15;87(4):450-3, A6. doi: 10.1016/s0002-9149(00)01402-8. Am J Cardiol. 2001. PMID: 11179533
670 results